16,660 Shares in Zoetis Inc. $ZTS Purchased by University of Texas Texas AM Investment Management Co.

University of Texas Texas AM Investment Management Co. purchased a new position in shares of Zoetis Inc. (NYSE:ZTS) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 16,660 shares of the company’s stock, valued at approximately $2,598,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Ingalls & Snyder LLC boosted its position in Zoetis by 65.7% during the second quarter. Ingalls & Snyder LLC now owns 21,832 shares of the company’s stock worth $3,405,000 after acquiring an additional 8,658 shares during the last quarter. Cabot Wealth Management Inc. raised its stake in Zoetis by 3.0% during the second quarter. Cabot Wealth Management Inc. now owns 66,613 shares of the company’s stock worth $10,388,000 after purchasing an additional 1,920 shares during the period. Brighton Jones LLC raised its stake in shares of Zoetis by 24.3% in the 2nd quarter. Brighton Jones LLC now owns 6,647 shares of the company’s stock valued at $1,037,000 after acquiring an additional 1,298 shares during the period. MQS Management LLC raised its stake in shares of Zoetis by 65.2% in the 2nd quarter. MQS Management LLC now owns 4,240 shares of the company’s stock valued at $661,000 after acquiring an additional 1,674 shares during the period. Finally, Linden Thomas Advisory Services LLC purchased a new stake in shares of Zoetis in the 2nd quarter valued at approximately $225,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Trading Down 0.2%

Shares of Zoetis stock opened at $146.14 on Friday. The company has a fifty day simple moving average of $148.18 and a 200-day simple moving average of $153.57. Zoetis Inc. has a 12-month low of $139.34 and a 12-month high of $184.40. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The stock has a market cap of $64.77 billion, a price-to-earnings ratio of 25.15, a PEG ratio of 2.35 and a beta of 0.90.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business had revenue of $2.46 billion during the quarter, compared to analysts’ expectations of $2.41 billion. During the same quarter in the prior year, the business posted $1.56 EPS. The company’s revenue for the quarter was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be issued a $0.50 dividend. The ex-dividend date is Friday, October 31st. This represents a $2.00 annualized dividend and a dividend yield of 1.4%. Zoetis’s dividend payout ratio is presently 34.42%.

Wall Street Analysts Forecast Growth

ZTS has been the topic of a number of research analyst reports. UBS Group reduced their price target on shares of Zoetis from $165.00 to $158.00 and set a “neutral” rating on the stock in a research note on Monday, October 20th. Leerink Partners downgraded shares of Zoetis from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Piper Sandler upped their target price on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Leerink Partnrs downgraded shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Zoetis in a report on Friday. Four research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $195.00.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.